| |
Newsroom /
Medical
/
Medical
/
Brain Hemorrhage - Drug Pipeline Analysis and Market Forecasts to 2016
Brain Hemorrhage - Drug Pipeline Analysis and Market Forecasts to 2016
The Brain Hemorrhage Market is Forecast to Show Modest Growth until 2016
Hyderabad,
AP,
India
(prbd.net)
25/05/2010
"Brain Hemorrhage - Drug Pipeline Analysis and Market Forecasts to 2016"
GlobalData estimates that the global brain hemorrhage market was valued at $373m in 2009 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 4% to reach $492m by 2016. This modest growth forecast is primarily attributed to a weak pipeline landscape. The existing market is weak due to lack of targeted therapies, poor awareness levels of the condition and the poor safety profiles of the existing therapies. The market is characterized by several off-label drugs and generics that treat the symptoms of the condition. Antihypertensive agents, antiepileptic agents, stool softeners, antidotes and analgesics are the most commonly employed therapies to treat the condition symptomatically.
GlobalData has found that the brain hemorrhage market has huge unmet needs, which implies that the market is not well served by the current products and that there is considerable scope for new entrants. Brain hemorrhage therapies are largely targeted at treating the symptoms of the condition. The market is dominated by generics and off-label medications which include antihypertensive agents, antiepileptic agents, stool softeners, antidotes and analgesics. In summary, the brain hemorrhage market is expected to be a relatively open market for new entrants until 2016 with huge opportunities for value capture.
GlobalData’s analysis shows that the brain hemorrhage developmental pipeline is weak with 25 molecules in various phases of clinical development, including 13 first-in-class molecules. These first-in-class molecules have a distinct advantage over the currently marketed products for brain hemorrhage in terms of providing better symptomatic management but not with respect to curing the condition. The pipeline includes chelating agents, nitric oxide releasing agents, calcium channel blockers, cGMP phosphodiesterase inhibitors, COX inhibitors, G protein-coupled receptor antagonists, PPAR-gamma agonists, ryanodine receptor relaxants and tissue plasminogen activators for the treatment of brain hemorrhage. Most of the clinical trials are being sponsored by universities and are not expected to affect the future brain hemorrhage therapeutic market significantly. Due to this, only a few branded products are expected to enter the brain hemorrhage market.
Most of the clinical studies in the brain hemorrhage market are being sponsored by universities and the National Institute of Neurological Disorders and Stroke (NINDS). Only a few companies, such as F. Hoffmann-La Roche Ltd. (Roche), Actelion Ltd. and Baxter International Inc., have important pipeline drugs for brain hemorrhage. The current competitive landscape consists entirely of generics and off-label therapies, none of which have a dominant position. The current emphasis has been on treating the symptoms of the condition without providing an absolute cure. Any company that successfully targets condition modification will become a major player in the brain hemorrhage market.
GlobalData’s report, “Brain Hemorrhage – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global brain hemorrhage market. The report identifies the key trends shaping and driving the global brain hemorrhage market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to significantly shift the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global brain hemorrhage sector.
Visit our Report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|